Colorectal Cancer Uses Dual Mechanisms to Evade Immunotherapy, Study Finds

A recent study published in *Nature Genetics* reveals that colorectal cancer employs a dual defense mechanism to resist immunotherapy, posing significant challenges for treatment. Colorectal cancer is one of the deadliest malignancies worldwide, particularly for patients with metastatic disease. While immunotherapy has revolutionized outcomes for many cancers, most metastatic colorectal cancer cases remain resistant to these interventions.

The research highlights two key mechanisms that enable colorectal tumors to evade immune system attacks. First, the tumors suppress immune responses by altering their microenvironment, making it less conducive for immune cells to function effectively. Second, they employ genetic adaptations that further enhance their ability to avoid detection and destruction by the immune system. These findings shed light on why current immunotherapy approaches have limited success against metastatic colorectal cancer and underscore the complexity of treating this aggressive disease.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: November 7, 2025

Related posts:

Biotech Updates: The Readout Reports on Sector Developments and Activities. Precision Medicine Targets Resistant Mutations in Lung Cancer Treatment Proposed Traffic Light Labeling System Aims to Regulate AI Mental Health Tools Genetic Regulation of Exosome Biogenesis Linked to Obesity and Insulin Resistance

Author

GOAI